What is the role of aldosterone antagonists (e.g., spironolactone, eplerenone) in the management of heart failure?

Aldosterone Antagonists in Heart Failure: Essential Mortality-Reducing Therapy

Aldosterone antagonists (spironolactone or eplerenone) are strongly recommended for all patients with symptomatic heart failure and reduced ejection fraction (LVEF ≤35-40%) to reduce mortality and hospitalizations, provided they have adequate renal function (eGFR >30 mL/min/1.73 m²) and serum potassium <5.0 mEq/L. 1

Primary Indications Based on Mortality Benefit

Heart Failure with Reduced Ejection Fraction (HFrEF)

For NYHA Class II-IV patients:

• LVEF ≤35% on optimal therapy with ACE inhibitors/ARBs and beta-blockers
• NYHA Class II patients require either prior cardiovascular hospitalization OR elevated natriuretic peptides to qualify 1
• Provides 30% relative risk reduction in mortality and 35% reduction in HF hospitalizations 2
• Number needed to treat: 9 patients for 2 years to prevent 1 death 2

Post-Myocardial Infarction:

• LVEF ≤40% with HF symptoms OR diabetes mellitus
• Initiate 3-14 days post-MI
• 15% relative risk reduction in mortality demonstrated with eplerenone 2, 1

Heart Failure with Mildly Reduced Ejection Fraction (HFmrEF)

For patients with LVEF 41-49%, aldosterone antagonists may be considered, particularly for those with LVEF on the lower end of this spectrum 3, 4. Post-hoc analysis of TOPCAT showed benefit in patients with LVEF 44-49%, primarily driven by cardiovascular mortality reduction 4.

Drug Selection: Spironolactone vs. Eplerenone

Both agents reduce mortality and hospitalizations equivalently, but differ in side effect profiles:

Spironolactone:

• First-line choice for most patients (lower cost, extensive evidence base)
• 10% incidence of gynecomastia/breast tenderness in men 2
• Dose: Start 12.5-25 mg daily, target 25-50 mg daily 1

Eplerenone:

• Preferred when spironolactone causes breast symptoms (more selective mineralocorticoid receptor antagonism) 2, 5
• Lower incidence of anti-androgen effects
• Dose: Start 25 mg daily, target 50 mg daily 1
• Recent evidence suggests superior effects on LV reverse remodeling and potentially lower cardiovascular mortality compared to spironolactone 6

Critical Safety Parameters and Monitoring

Absolute Contraindications

• Serum potassium >5.0 mEq/L at initiation 1
• **eGFR <30 mL/min/1.73 m²** (or creatinine >2.5 mg/dL in men, >2.0 mg/dL in women) 1
• Concomitant strong CYP3A inhibitors 7
• AVOID triple therapy with ACE inhibitor + ARB + aldosterone antagonist 1

Initiation Protocol

Pre-treatment requirements:

• Check serum potassium and renal function
• Discontinue potassium supplements (or reduce significantly) 1
• Counsel patients to avoid high-potassium foods and NSAIDs 1

Starting doses:

• Standard renal function (eGFR ≥50): Spironolactone 12.5-25 mg daily OR eplerenone 25 mg daily 1
• Marginal renal function (eGFR 30-49): Consider every-other-day dosing initially 1

Monitoring Schedule

Intensive early monitoring is mandatory:

• Days 2-3 and day 7 after initiation: Check potassium and creatinine 1
• Weeks 1 and 4 after each dose increase 2, 1
• Monthly for first 3 months, then every 3 months thereafter 1
• Reinitiate intensive monitoring cycle when adjusting ACE inhibitor/ARB doses 1

Managing Hyperkalemia

Potassium 5.5-6.0 mEq/L:

• Halve the dose (e.g., 25 mg every other day) 2
• Monitor blood chemistry closely

Potassium >6.0 mEq/L:

• Stop aldosterone antagonist immediately 2
• Specific treatment of hyperkalemia may be needed
• Monitor closely; consider restarting at reduced dose after resolution for ≥72 hours 1

Creatinine >220 μmol/L (2.5 mg/dL):

• Halve dose and monitor closely 2

Creatinine >310 μmol/L (3.5 mg/dL):

• Stop immediately 2

Common Clinical Pitfalls

Real-World Hyperkalemia Risk

While clinical trials reported 2-5% hyperkalemia rates, population-based studies show 24-36% incidence in routine practice 1. The Ontario study demonstrated that after widespread spironolactone adoption post-RALES, hospitalizations for hyperkalemia increased from 2.4 to 11 per 1,000 patients, with associated mortality rising from 0.3 to 2 per 1,000 8.

High-risk patients for hyperkalemia:

• Elderly patients
• Baseline renal dysfunction (even if eGFR >30)
• Diabetes
• Concomitant NSAIDs or moderate CYP3A inhibitors 1
• Higher doses of ACE inhibitors (captopril ≥75 mg, enalapril/lisinopril ≥10 mg daily) 1

Critical Patient Instructions

Patients must be instructed to temporarily stop aldosterone antagonists during:

• Episodes of diarrhea or dehydration 8, 1
• When loop diuretic therapy is interrupted 1
• Acute illness causing volume depletion

Dose Titration Strategy

After 4-8 weeks at starting dose, if potassium remains <5.0 mEq/L and renal function stable:

• Target dose: Spironolactone 25-50 mg daily or eplerenone 50 mg daily 2, 1
• Do not increase if any worsening renal function or rising potassium 2

Evidence Base

The mortality benefit is established by landmark trials:

• RALES (spironolactone): 30% mortality reduction in NYHA III-IV 2
• EPHESUS (eplerenone): 15% mortality reduction post-MI 2
• EMPHASIS-HF (eplerenone): Extended benefit to NYHA Class II patients 9, 10

The 2013 ACC/AHA guidelines provide the most comprehensive and recent guidance on aldosterone antagonist use, emphasizing their Class I recommendation status for appropriate HFrEF patients 1. The 2022 guidelines further support their use across the HF spectrum, including consideration in HFmrEF 3, 4.